at7519
Small moleculeexperimental
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2006 (NCT00390117)
Timeline
Indications
Mechanism of action
- Cyclin-dependent kinaseINHIBITOR
Cyclin-dependent kinase inhibitor
- Cyclin-dependent kinase 1 (CDK1) ↗
- Cyclin-dependent kinase 4 (CDK4) ↗
- Cyclin-dependent kinase 2 (CDK2) ↗
- Cyclin-dependent-like kinase 5 (CDK5) ↗
- Cyclin-dependent kinase 6 (CDK6) ↗
- Cyclin-dependent kinase 7 (CDK7) ↗
- Cyclin-dependent kinase 3 (CDK3) ↗
- Cyclin-dependent kinase 16 (CDK16) ↗
- Cyclin-dependent kinase 18 (CDK18) ↗
- Cyclin-dependent kinase 8 (CDK8) ↗
- Cyclin-dependent kinase 17 (CDK17) ↗
- Cyclin-dependent kinase 11B (CDK11B) ↗
- Cyclin-dependent kinase 15 (CDK15) ↗
- Cyclin-dependent kinase 19 (CDK19) ↗
- Cyclin-dependent kinase 14 (CDK14) ↗
- Cyclin-dependent kinase 9 (CDK9) ↗
- Cyclin-dependent kinase 10 (CDK10) ↗
- Cyclin-dependent kinase 13 (CDK13) ↗
- Cyclin-dependent kinase 20 (CDK20) ↗
- Cyclin-dependent kinase 12 (CDK12) ↗
- Cyclin-dependent kinase 6
- Cyclin-dependent kinase 9
- Cyclin-dependent kinase 2
- Cyclin-dependent kinase 1
- Cyclin-dependent kinase 3
- Cyclin-dependent kinase 7
- Cyclin-dependent kinase 4
- Cyclin-dependent kinase 5
- Serine/threonine-protein kinase PCTAIRE-1
- Serine/threonine-protein kinase PCTAIRE-3
- Cell division protein kinase 8
- PITSLRE serine/threonine-protein kinase CDC2L1
- Serine/threonine-protein kinase PFTAIRE-2
- Cell division cycle 2-like protein kinase 6
- Serine/threonine-protein kinase PFTAIRE-1
- Serine/threonine-protein kinase PCTAIRE-2
- Cyclin-dependent kinase 10
- Cyclin-dependent kinase 13
- Cyclin-dependent kinase 2 and 4 (CDK2 and CDK4)
- CDK2/CDK4
- Cyclin-dependent kinase 20
- Cyclin-dependent kinase 12
- Cyclin-dependent kinase 4/6
- Cyclin-dependent kinase 8/19
- CDK4/CDK9
- Cyclin-dependent kinase 12/13
- CDK4/CDK1
- Cyclin-dependent kinase 2/4/6
Chemistry & pharmacology
Loading structure…
SMILES
O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl- Mol. weight
- 382.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL445813 ↗
Also known as
- 4-(2,6-dichlorobenzoylamino)-1h-pyrazole-3-carboxylic acid piperidin-4-ylamide
- at7519
- at7519
- at7519
- at7519
- at 7519
- at-7519
- at-7519
- at-7519
- at7519m
- at7519m
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02503709 | Phase 1 | Apr 8, 2016 | Harvard University, National Cancer Institute (NCI) |
| NCT01627054 | Phase 2 | Aug 1, 2012 | Astex Pharmaceuticals, Inc., Canadian Cancer Trials Group, University of Manitoba |
| NCT01652144 | Phase 2 | Aug 1, 2012 | Astex Pharmaceuticals, Inc., Canadian Cancer Trials Group, University of Toronto |
| NCT01183949 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2010 | Astex Pharmaceuticals, Inc., Multiple Myeloma Research Consortium |
| NCT00390117 | Phase 1 | Aug 1, 2006 | Canadian Cancer Trials Group, McMaster University, University of Toronto |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astex Pharmaceuticals, Inc. | For profit | 3 | 1 | 1 | 2010 |
| Canadian Cancer Trials Group | Academic/Hospital | 3 | 3 | 2 | 2006 |
| University of Toronto | Academic/Hospital | 2 | 0 | 2 | 2006 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| McMaster University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Multiple Myeloma Research Consortium | Academic/Hospital | 1 | 0 | 1 | 2010 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2016 |
| University of Manitoba | Academic/Hospital | 1 | 0 | 1 | 2012 |
8 organizations
Page 1 / 1